<h1>Robotic Neurointervention Trial Shows Equal Safety, Cuts Operator Radiation by 96% Under GCP Standards</h1> A multicenter randomized controlled trial evaluated a neurointerventional robotic system developed by a Chinese biomedical company in collaboration with several hospitals. The trial, conducted under Good Clinical Practice standards and registered as NCT05778214, enrolled 128 patients undergoing cerebral angiography, comparing robot-assisted procedures to conventional manual operations. The study demonstrated that the robotic system is non-inferior in safety and efficacy, achieving 100% clinical success in both groups, while reducing the primary operator's radiation exposure by 96% without increasing patient risk. The system received regulatory market authorization in August 2024. Technical innovations include a master-slave architecture and a proprietary catheter interface enabling precise control. The company plans further product iterations and regulatory submissions to expand the system's neurointerventional applications. This trial's publication in a leading international neurointerventional journal marks a significant milestone for robotic-assisted neurovascular procedures and supports the system's potential to become a standard clinical tool globally.